10-Q · May 7, 2026
Rapport Therapeutics reported a collaboration revenue of $20 million for Q1 2026, resulting in an improved net loss of $19.9 million from a loss of $24.1 million in the prior year. The company continues to invest…
Earnings analysis · 10-Q
RAPP earnings analysis
Filed August 5, 2026 · Our reading of the company's report
The latest report
Rapport reported no Q2 collaboration revenue and a net loss of $56.6 million ($1.19 per diluted share), versus a $26.7 million loss a year earlier, as R&D spending increased to $51.4 million from $22.7 million to…
Read full summary
Rapport reported no Q2 collaboration revenue and a net loss of $56.6 million ($1.19 per diluted share), versus a $26.7 million loss a year earlier, as R&D spending increased to $51.4 million from $22.7 million to support RAP-219’s Phase 3 program. The company generated $20.0 million of Tenacia collaboration revenue in the first half, but development intensity drove six-month operating cash use up to $54.5 million from $45.3 million. Liquidity remains strong at $436.1 million with runway projected into the second half of 2029, while the key near-term value drivers are bipolar-mania topline data expected in October 2026 and FOS open-label data expected in Q4 2026.
Reported figures
- Earnings per share
- $-1.19
What stood out
-
RAP-219 Phase 3 program initiated
RAP-219 entered Phase 3 trials in drug-resistant focal-onset seizures during Q2 2026. Management expects topline bipolar-mania Phase 2 data in October 2026 and data from the FOS open-label safety study in Q4 2026.
-
Cash runway projected into 2H 2029
Cash, cash equivalents and short-term investments were $436.1 million at June 30, 2026. Management believes this balance funds operations and capital expenditures into the second half of 2029.
-
Tenacia deal adds non-dilutive funding
The Tenacia China license generated $20.0 million of collaboration revenue in the first six months of 2026; Rapport is also eligible for up to $308.0 million in sales milestones plus mid-single-digit to mid-teens royalties.
-
Longer RAP-219 half-life supports dosing profile
RAP-219’s estimated half-life increased to 22 days from the prior 14-day estimate, with management citing sustained therapeutic plasma concentrations during the 8-week follow-up period.
-
Interest income rose to $4.2 million
Interest income increased $1.4 million year over year to $4.2 million in Q2, partially offsetting the higher development spend.
What to watch
-
Loss and expense base increased sharply
Q2 net loss widened to $56.6 million, or $1.19 per diluted share, from a $26.7 million loss a year earlier. Total operating expense more than doubled to $60.8 million from $29.5 million.
-
Phase 3 spending materially accelerates
R&D expense rose $28.7 million year over year to $51.4 million, led by a $24.4 million increase in RAP-219 program costs; $22.3 million of that increase was clinical-trial cost, principally Phase 3 start-up and other RAP-219 studies.
-
Operating cash burn increased
Six-month operating cash use rose to $54.5 million from $45.3 million a year earlier. The company had $436.1 million of cash and short-term investments but states it will need substantial additional capital in the future.
-
Pipeline remains exposed to trial and FDA risk
The business remains fully dependent on clinical and regulatory execution: RAP-219 is only now in Phase 3 for FOS, while the company previously received an FDA clinical hold on the DPNP IND in Q4 2024, although that hold was removed in December 2025.
-
$150.0 million ATM creates dilution capacity
Potential future dilution remains material: the company had not sold shares through its ATM as of June 30, 2026, but has a sales agreement prospectus permitting up to $150.0 million of common-stock issuance.
-
Janssen milestones could pressure future cash
RAP-219 carries substantial contingent obligations under the Janssen license, including up to $76.0 million in development milestones and $40.0 million in sales milestones for the lead TARPγ8 candidate.
Management's outlook
No numeric revenue or EPS outlook was provided in the 10-Q. Management expects $436.1 million of cash, cash equivalents and short-term investments at June 30, 2026 to fund operating expenses and capital expenditures into the second half of 2029; bipolar-mania Phase 2 topline data are expected in October 2026, open-label FOS data in Q4 2026, and a PGTCS Phase 3 initiation in the first half of 2027.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.